BEAM FY2025 EPS Forecast Decreased by Cantor Fitzgerald

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a report released on Wednesday, May 7th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will post earnings per share of ($3.48) for the year, down from their prior forecast of ($3.27). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share.

A number of other equities analysts have also weighed in on the company. Barclays reduced their price objective on Beam Therapeutics from $31.00 to $25.00 and set an “equal weight” rating for the company in a research note on Wednesday. Wedbush reissued an “outperform” rating and issued a $57.00 price target on shares of Beam Therapeutics in a report on Monday, March 10th. Scotiabank raised shares of Beam Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $40.00 price objective on the stock in a research note on Monday, March 10th. Bank of America upgraded shares of Beam Therapeutics from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Friday, March 28th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Monday, April 7th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $48.75.

Beam Therapeutics Price Performance

NASDAQ:BEAM opened at $17.42 on Friday. The firm has a market capitalization of $1.75 billion, a P/E ratio of -9.90 and a beta of 2.35. The company’s fifty day moving average price is $20.07 and its 200-day moving average price is $24.32. Beam Therapeutics has a 1-year low of $13.53 and a 1-year high of $35.25.

Beam Therapeutics (NASDAQ:BEAM) last issued its earnings results on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.13). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm had revenue of $7.47 million during the quarter, compared to analysts’ expectations of $14.69 million. During the same quarter in the prior year, the company earned ($1.21) EPS. Beam Therapeutics’s quarterly revenue was up 1.4% on a year-over-year basis.

Insider Activity at Beam Therapeutics

In other news, President Giuseppe Ciaramella sold 7,434 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $136,413.90. Following the transaction, the president now directly owns 190,216 shares of the company’s stock, valued at approximately $3,490,463.60. This trade represents a 3.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO John M. Evans sold 30,663 shares of the business’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total transaction of $562,666.05. Following the transaction, the chief executive officer now owns 986,249 shares in the company, valued at $18,097,669.15. The trade was a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,771 shares of company stock valued at $803,198. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Beam Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Wealthfront Advisers LLC acquired a new stake in shares of Beam Therapeutics in the 4th quarter worth $41,000. GF Fund Management CO. LTD. acquired a new stake in Beam Therapeutics during the fourth quarter worth about $43,000. CWM LLC raised its stake in Beam Therapeutics by 79.8% during the first quarter. CWM LLC now owns 2,684 shares of the company’s stock worth $52,000 after purchasing an additional 1,191 shares during the period. Sterling Capital Management LLC boosted its holdings in Beam Therapeutics by 816.0% in the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company’s stock valued at $60,000 after purchasing an additional 2,146 shares during the last quarter. Finally, Amalgamated Bank increased its holdings in shares of Beam Therapeutics by 20.4% during the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company’s stock worth $62,000 after buying an additional 534 shares during the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.